Daxor to Present at H.C. Wainwright 22nd Annual Global Investment Conference
Daxor Corporation (NYSE: DXR) will participate in the virtual H.C. Wainwright 22nd Annual Global Investment Conference on September 15, 2020, at 2:00 PM ET. During this event, President & CEO Michael Feldschuh will present updates regarding the company's BVA-100 technology, a diagnostic tool for blood volume measurement. The conference runs from September 14-16, 2020, featuring opportunities for one-on-one meetings with investors. Daxor's technology aims to enhance treatment strategies and patient outcomes in critical medical conditions.
- None.
- None.
NEW YORK, Sept. 10, 2020 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, today announces that Michael Feldschuh, Daxor’s President & Chief Executive Officer, will present at the virtual H.C. Wainwright 22nd Annual Global Investment Conference on Tuesday, September 15, 2020, at 2:00 PM ET.
The Company will present virtually and provide updates about recent developments and key highlights including progress with BVA-100 as well as be available to participate in one-on-one meetings.
Event: H.C. Wainwright 22nd Annual Global Investment Conference
Date: Tuesday, September 15th, 2020
Presentation: 2:00 PM ET - 2:20 PM ET
Register here:
https://www.meetmax.com/sched/event_61861/investor_reg_new.html?attendee_role_id=INVESTOR
HC Wainwright will take place on September 14th through the 16th.
About Daxor Corporation
Daxor Corporation (NYSE: DXR) is an innovative medical instrumentation and biotechnology company focused on blood volume measurement. We developed and market the BVA-100® (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms. The BVA technology has the potential to improve hospital performance metrics in a broad range of surgical and medical conditions, including heart failure and critical care, by informing treatment strategies, resulting in significantly improved patient outcomes. Our mission is to partner with clinicians to incorporate BVA technology into standard clinical practice and improve the quality of life for patients. For more information, please visit our website at Daxor.com.
Forward-Looking Statements
Certain statements in this release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the impact of hiring sales staff and expansion of our distribution channels. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risks associated with our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, FDA regulatory actions, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and additional other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Daxor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Relations Contact:
Bret Shapiro
Sr. Managing Partner, CORE IR
516-222-2560
brets@coreir.com
FAQ
When is Daxor Corporation presenting at the H.C. Wainwright conference?
What key topics will Daxor discuss during the conference?
How can investors register for the H.C. Wainwright conference?
What is the BVA-100 technology developed by Daxor?
What is the purpose of Daxor's technology in medical practice?
